DACA Student under Anti-ICE Terrorism Investigation Chooses Mexico Deportation over Further Disclosure

DACA Student under Anti-ICE Terrorism Investigation Chooses Mexico Deportation over Further Disclosure

Rather than face court proceedings that would further disclose why an FBI counterterrorism investigation has targeted him, San Antonio DACA recipient Sergio "Mapache" Salazar chose to take deportation to Mexico instead. The Mexico-born Salazar was brought to the United States when he was two and has lived in San Antonio ever since, and received temporary legal status under the Deferred Action for Childhood Arrivals (DACA) program.

As the Center for Immigration Studies reported here and again here , the San Antonio FBI’s Joint Terrorism Task Force (JTTF) arrested the 18-year-old DACA recipient August 3 on an immigration charge, while he was protesting at an ICE facility. They did so after examining online postings allegedly threatening ICE agents and offering instructional videos on how to make bombs. At an August 22 hearing at which Salazar argued he should be released on a low bond, ICE attorneys were preparing to counter his argument with the release of 21 pages of the online postings. But when they saw the pages, Salazar’s attorneys for the immigration advocacy group RAICES abruptly withdrew the bond request, leaving the youth in custody as the FBI counterterrorism investigation continued.

At a follow-up hearing on Friday, September 14, Salazar agreed to involuntary deportation without a fight. The online postings, therefore, will not become public, and the FBI counterterrorism investigation likely will not be concluded either. But it is also highly unlikely that Salazar will ever legally live in the United States again, a consequence that must have seemed preferable to […]

THE POWER OF STEM CELLS & EXOSOMES
Scientists have recently developed advanced protocols harnessing the power of exosomes to create a new class of therapeutics to improve the effectiveness of stem cell therapy. In particular, they have developed new protocols for neurological diseases such as Alzheimer´s, Parkinson´s, Autism and Multiple Sclerosis. Read More